Arbutus Biopharma
preliminary phase a triple combination data | Arbutus Biopharma
Company
Deck Type
Sector
Industry
Deck date
November 2022
Slide
10 of 15
Related slides by other companies
Compass Therapeutics
Investor Presentation
May 2022
phase combination safety data | Compass Therapeutics
RenovoRx
IPO
August 2021
promising data from phase and observational registry studies advanced clinical development program to phase median overall survival gem alone | RenovoRx
ATAI
Investor Presentation
October 2023
in cash as of provides expected runway into life sciences operational focus program guidance | ATAI
ATAI
Investor Presentation
March 2023
group average changes in beta power for low dose and high dose groups per time point average differences in each time point is compared to zero and time points with significant changes test were marked with asterisk preliminary data subject to change phase the effect was also time dependent showing a rapid onset of effect a delayed pharmacodynamic curve | ATAI
Other recent decks by Arbutus Biopharma
See all presentations (8 decks)
Investor Presentation
June 2024
Investor Presentation
January 2024
Investor Presentation
November 2023
Investor Presentation
October 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights